Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.
Díaz-Beyá M, Labopin M, Maertens J, Aljurf M, Passweg J, Dietrich B, Schouten H, Socié G, Schaap N, Schwerdtfeger R, Volin L, Michallet M, Polge E, Sierra J, Mohty M, Esteve J, Nagler A; Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Br J Haematol. 2020 Jun;189(5):920-925. doi: 10.1111/bjh.16433. Epub 2020 Feb 5.
Acute Myeloid Leukemia with t(6;9)(p23;q34.1); DEK-NUP214: The Pathogenesis and Potential.
Gardner JA, Donnelly L, Goetz R, Waller B, Devitt K.
J Assoc Genet Technol. 2020;46(2):98-102.
Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy.
Day JW, Fox TA, Gupta R, Khwaja A, Wilson AJ, Kottaridis PD.
Leuk Res Rep. 2022 Feb 7;17:100291. doi: 10.1016/j.lrr.2022.100291. eCollection 2022.
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities.
Baldazzi C, Luatti S, Marzocchi G, Grassi A, Cavo M, Testoni N.
Cancer Genet. 2022 Apr;262-263:35-39. doi: 10.1016/j.cancergen.2021.12.006. Epub 2021 Dec 22.
[Classification of myeloid leukemias].
Kuriyama K.
Nihon Rinsho. 2009 Oct;67(10):1853-62.
Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34).
Visconte V, Shetty S, Przychodzen B, Hirsch C, Bodo J, Maciejewski JP, Hsi ED, Rogers HJ.
Int J Lab Hematol. 2017 Aug;39(4):409-417. doi: 10.1111/ijlh.12641. Epub 2017 Mar 20.
A novel variant translocation (1;9)(p22;q34) resulting in a DEK/NUP214 fusion gene in a patient with acute myeloid leukemia: A case report.
Hao Q, Zhang Q, Li C, Wei S, Li Q, Song Y, Mi Y.
Oncol Lett. 2017 Dec;14(6):7021-7024. doi: 10.3892/ol.2017.7133. Epub 2017 Oct 3.
